Tyra Biosciences (TYRA) Fundamental Analysis: Revenue, Earnings & Valuation

3.70 / 10

Netural

Fundamental metrics rate neutral with a 3.7/10 score. Cash‑to‑market and inventory turnover are strong, yet revenue‑to‑market, PB‑ROE and gross profit margin lag. Income‑tax ratio is modest. Overall fundamentals are challenging, suggesting selective exposure.

Analysis Checks(6/10)

Revenue-MV

Value-0.11

Score1/3

Weight12.88%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value134.00

Score3/3

Weight3.33%

1M Return1.54%

Inventory turnover ratio

Value103.94

Score3/3

Weight17.09%

1M Return6.74%

Gross profit margin (%)

Value41.83

Score1/3

Weight-1.21%

1M Return-0.63%

PB-ROE

Value3.87

Score0/3

Weight8.60%

1M Return3.23%

Income tax / Total profit (%)

Value21.05

Score1/3

Weight-0.99%

1M Return-0.50%

Fixed assets turnover ratio

Value9306.28

Score3/3

Weight2.20%

1M Return1.06%

Cost of sales ratio (%)

Value64.41

Score3/3

Weight9.88%

1M Return4.32%

Asset-MV

Value-0.55

Score2/3

Weight33.04%

1M Return12.22%

Cash-MV

Value0.02

Score2/3

Weight15.18%

1M Return5.94%

Is TYRA fundamentally strong?

TYRA scores 3.70/10 on fundamentals and holds a Fair valuation at present. Backed by its -39.83% ROE, 0.00% net margin, -17.79 P/E ratio, 8.23 P/B ratio, and -33.11% earnings growth, these metrics solidify its Netural investment rating.